ATE139255T1 - Oligonukleotidanaloga mit neuartigen bindungen - Google Patents

Oligonukleotidanaloga mit neuartigen bindungen

Info

Publication number
ATE139255T1
ATE139255T1 AT90916934T AT90916934T ATE139255T1 AT E139255 T1 ATE139255 T1 AT E139255T1 AT 90916934 T AT90916934 T AT 90916934T AT 90916934 T AT90916934 T AT 90916934T AT E139255 T1 ATE139255 T1 AT E139255T1
Authority
AT
Austria
Prior art keywords
oligonucleotide compounds
bindings
novel
oligonucleotide analogues
nucleotides
Prior art date
Application number
AT90916934T
Other languages
English (en)
Inventor
Mark Matteucci
Original Assignee
Gilead Sciences Inc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Priority claimed from US07/559,957 external-priority patent/US5264564A/en
Application filed by Gilead Sciences Inc filed Critical Gilead Sciences Inc
Application granted granted Critical
Publication of ATE139255T1 publication Critical patent/ATE139255T1/de

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07H—SUGARS; DERIVATIVES THEREOF; NUCLEOSIDES; NUCLEOTIDES; NUCLEIC ACIDS
    • C07H21/00—Compounds containing two or more mononucleotide units having separate phosphate or polyphosphate groups linked by saccharide radicals of nucleoside groups, e.g. nucleic acids
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07H—SUGARS; DERIVATIVES THEREOF; NUCLEOSIDES; NUCLEOTIDES; NUCLEIC ACIDS
    • C07H19/00—Compounds containing a hetero ring sharing one ring hetero atom with a saccharide radical; Nucleosides; Mononucleotides; Anhydro-derivatives thereof
    • C07H19/02—Compounds containing a hetero ring sharing one ring hetero atom with a saccharide radical; Nucleosides; Mononucleotides; Anhydro-derivatives thereof sharing nitrogen
    • C07H19/04—Heterocyclic radicals containing only nitrogen atoms as ring hetero atom
    • C07H19/06—Pyrimidine radicals
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/12—Antivirals
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07H—SUGARS; DERIVATIVES THEREOF; NUCLEOSIDES; NUCLEOTIDES; NUCLEIC ACIDS
    • C07H19/00—Compounds containing a hetero ring sharing one ring hetero atom with a saccharide radical; Nucleosides; Mononucleotides; Anhydro-derivatives thereof
    • C07H19/02—Compounds containing a hetero ring sharing one ring hetero atom with a saccharide radical; Nucleosides; Mononucleotides; Anhydro-derivatives thereof sharing nitrogen
    • C07H19/04—Heterocyclic radicals containing only nitrogen atoms as ring hetero atom
    • C07H19/16—Purine radicals
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N15/00—Mutation or genetic engineering; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification; Use of hosts therefor
    • C12N15/09—Recombinant DNA-technology
    • C12N15/11—DNA or RNA fragments; Modified forms thereof; Non-coding nucleic acids having a biological activity

Landscapes

  • Chemical & Material Sciences (AREA)
  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Organic Chemistry (AREA)
  • Engineering & Computer Science (AREA)
  • Genetics & Genomics (AREA)
  • Molecular Biology (AREA)
  • General Health & Medical Sciences (AREA)
  • Biochemistry (AREA)
  • Biotechnology (AREA)
  • Biomedical Technology (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Zoology (AREA)
  • General Engineering & Computer Science (AREA)
  • Medicinal Chemistry (AREA)
  • Veterinary Medicine (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Public Health (AREA)
  • Animal Behavior & Ethology (AREA)
  • Wood Science & Technology (AREA)
  • Physics & Mathematics (AREA)
  • Plant Pathology (AREA)
  • Microbiology (AREA)
  • Virology (AREA)
  • Communicable Diseases (AREA)
  • Oncology (AREA)
  • Biophysics (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Saccharide Compounds (AREA)
  • Nitrogen Condensed Heterocyclic Rings (AREA)
AT90916934T 1989-10-24 1990-10-24 Oligonukleotidanaloga mit neuartigen bindungen ATE139255T1 (de)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US42628689A 1989-10-24 1989-10-24
US44894189A 1989-12-11 1989-12-11
US07/559,957 US5264564A (en) 1989-10-24 1990-07-30 Oligonucleotide analogs with novel linkages

Publications (1)

Publication Number Publication Date
ATE139255T1 true ATE139255T1 (de) 1996-06-15

Family

ID=27411504

Family Applications (1)

Application Number Title Priority Date Filing Date
AT90916934T ATE139255T1 (de) 1989-10-24 1990-10-24 Oligonukleotidanaloga mit neuartigen bindungen

Country Status (8)

Country Link
EP (1) EP0498843B1 (de)
JP (1) JPH05504553A (de)
KR (1) KR920702409A (de)
AT (1) ATE139255T1 (de)
AU (1) AU653504B2 (de)
CA (1) CA2071483C (de)
DE (1) DE69027443T2 (de)
WO (1) WO1991006629A1 (de)

Families Citing this family (71)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5495009A (en) * 1989-10-24 1996-02-27 Gilead Sciences, Inc. Oligonucleotide analogs containing thioformacetal linkages
PT98562B (pt) * 1990-08-03 1999-01-29 Sanofi Sa Processo para a preparacao de composicoes que compreendem sequencias de nucleo-sidos com cerca de 6 a cerca de 200 bases resistentes a nucleases
EP0549686A4 (en) * 1990-09-20 1995-01-18 Gilead Sciences Inc Modified internucleoside linkages
US5495006A (en) * 1991-09-27 1996-02-27 Allelix Biopharmaceuticals, Inc. Antiviral polynucleotide conjugates
EP0691979A1 (de) * 1993-03-31 1996-01-17 Sanofi Neue 5'-substituierte nucleoside und daraus hergestellte oligomere
US5580972A (en) * 1993-06-14 1996-12-03 Nexstar Pharmaceuticals, Inc. Purine nucleoside modifications by palladium catalyzed methods
US5719273A (en) * 1993-06-14 1998-02-17 Nexstar Pharmaceuticals, Inc. Palladium catalyzed nucleoside modifications methods using nucleophiles and carbon monoxide
US6605708B1 (en) * 1993-07-28 2003-08-12 Hybridon, Inc. Building blocks with carbamate internucleoside linkages and oligonucleotides derived therefrom
US5646269A (en) * 1994-04-28 1997-07-08 Gilead Sciences, Inc. Method for oligonucleotide analog synthesis
US5716824A (en) * 1995-04-20 1998-02-10 Ribozyme Pharmaceuticals, Inc. 2'-O-alkylthioalkyl and 2-C-alkylthioalkyl-containing enzymatic nucleic acids (ribozymes)
US6251939B1 (en) 1995-06-07 2001-06-26 Promega Biosciences, Inc. Carbamate-based cationic lipids
EP0835305B1 (de) 1995-06-29 2005-11-23 Immunex Corporation Apoptosis induzierendes cytokin
US5959100A (en) 1996-03-27 1999-09-28 Nexstar Pharmaceuticals, Inc. Pyrimidine nucleosides as therapeutic and diagnostic agents
US5945527A (en) * 1996-05-30 1999-08-31 Nexstar Pharmaceuticals, Inc. Palladium catalyzed nucleoside modification methods using nucleophiles and carbon monoxide
WO1999060127A2 (en) 1998-05-15 1999-11-25 Genentech, Inc. Il-17 homologous polypeptides and therapeutic uses thereof
US6384203B1 (en) 1999-05-12 2002-05-07 Immunex Corporation Family of immunoregulators designated leukocyte immunoglobulin-like receptors (LIR)
US6007992A (en) * 1997-11-10 1999-12-28 Gilead Sciences, Inc. Pyrimidine derivatives for labeled binding partners
US6028183A (en) 1997-11-07 2000-02-22 Gilead Sciences, Inc. Pyrimidine derivatives and oligonucleotides containing same
EP3112468A1 (de) 1998-05-15 2017-01-04 Genentech, Inc. Il-17-homologe polypeptide und therapeutische verwendung davon
EP1865061A3 (de) 1998-05-15 2007-12-19 Genentech, Inc. IL-17-homologe Polypeptide und ihre therapeutische Verwendung
US20020172678A1 (en) 2000-06-23 2002-11-21 Napoleone Ferrara EG-VEGF nucleic acids and polypeptides and methods of use
PT1105485E (pt) 1998-08-21 2006-11-30 Immunex Corp Dna e polipeptídeos de il-1 epsilon humana
US6020483A (en) 1998-09-25 2000-02-01 Nexstar Pharmaceuticals, Inc. Nucleoside modifications by palladium catalyzed methods
JP4942248B2 (ja) 1999-03-26 2012-05-30 ザ・ヘンリー・エム・ジャクソン・ファンデイション・フォー・ジ・アドヴァンスメント・オヴ・ミリタリー・メディシン、インコーポレイテッド 前立腺特異的遺伝子、ｐｃｇｅｍ１、ならびに前立腺癌を検出、治療および予防するための、ｐｃｇｅｍ１の使用方法
EP1956030B1 (de) 1999-06-15 2009-11-11 Genentech, Inc. Sekretierte und Transmembran-Polypeptide sowie Nukleinsäuren zu deren Kodierung
CA2490909A1 (en) 1999-12-01 2001-06-07 Genentech, Inc. Secreted and transmembrane polypeptides and nucleic acids encoding the same
EP2290081A3 (de) 1999-12-23 2012-08-01 Genentech, Inc. IL-17-homologe Polypeptide und ihre therapeutische Verwendung
AU4945001A (en) 2000-03-22 2001-10-03 Curagen Corp Angiogenesis associated proteins, and nucleic acids encoding the same
DE60136281D1 (de) 2000-08-24 2008-12-04 Genentech Inc Methode zur inhibierung von il-22 induziertem pap1
EP1944317A3 (de) 2000-09-01 2008-09-17 Genentech, Inc. Sekretierte und Transmembran-Polypeptide sowie Nukleinsäure zu deren Kodierung
AU2002303929B9 (en) 2001-05-31 2007-01-25 E. R. Squibb & Sons, L.L.C. Cytotoxins, prodrugs, linkers and stabilizers useful therefor
US20070160576A1 (en) 2001-06-05 2007-07-12 Genentech, Inc. IL-17A/F heterologous polypeptides and therapeutic uses thereof
EP2000482A1 (de) 2001-06-20 2008-12-10 Genentech, Inc. Zusammensetzungen und Verfahren zur Behandlung und Diagnose von Tumoren
NZ531674A (en) 2001-09-18 2009-03-31 Genentech Inc Compositions and methods for the diagnosis and treatment of tumor
KR100623128B1 (ko) 2002-01-02 2006-09-14 제넨테크, 인크. 종양의 진단 및 치료 방법 및 이를 위한 조성물
US7303896B2 (en) 2002-02-25 2007-12-04 Genentech, Inc. Nucleic acid encoding novel type-1 cytokine receptor GLM-R
AU2003230874A1 (en) 2002-04-16 2003-11-03 Genentech, Inc. Compositions and methods for the diagnosis and treatment of tumor
KR20050004914A (ko) 2002-06-07 2005-01-12 제넨테크, 인크. 종양의 진단 및 치료 방법 및 이를 위한 조성물
WO2004096124A2 (en) 2003-04-01 2004-11-11 Genentech, Inc. Compositions and methods for the diagnosis and treatment of tumor
MXPA06000347A (es) 2003-07-08 2006-03-28 Genentech Inc Polipeptidos heterologos il-17 a/f y usos terapeuticos de los mismos.
EP1689432B1 (de) 2003-11-17 2009-12-30 Genentech, Inc. Zusammensetzungen und verfahren zur behandlung von tumoren hämatopoetischen ursprungs
CA2597325A1 (en) 2005-03-10 2006-09-21 Genentech, Inc. Methods and compositions for modulating vascular integrity
US7858843B2 (en) 2005-06-06 2010-12-28 Genentech, Inc. Gene disruptions, compositions and methods relating thereto
JP2009504183A (ja) 2005-08-15 2009-02-05 ジェネンテック・インコーポレーテッド 遺伝子破壊、それに関連する組成物および方法
AU2006294554B2 (en) 2005-09-26 2013-03-21 E. R. Squibb & Sons, L.L.C. Antibody-drug conjugates and methods of use
CA2630432A1 (en) 2005-11-21 2007-07-19 Genentech, Inc. Novel gene disruptions, compositions and methods relating thereto
NZ621483A (en) 2005-12-02 2015-10-30 Genentech Inc Compositions and methods for the treatment of diseases and disorders associated with cytokine signaling involving antibodies that bind to il-22 and il-22r
EP1988768A2 (de) 2006-02-17 2008-11-12 Genentech, Inc. Genunterbrechungen sowie dazugehörige zusammensetzungen und verfahren
EP2007428A2 (de) 2006-04-05 2008-12-31 Genentech, Inc. Verfahren zur verwendung von boc/cdo zur modulation der hedgehog-signalisierung
US20090288176A1 (en) 2006-04-19 2009-11-19 Genentech, Inc. Novel Gene Disruptions, Compositions and Methods Relating Thereto
EP2061906B1 (de) 2006-09-12 2011-08-31 Genentech, Inc. Verfahren und zusammensetzungen zur diagnose und behandlung von lungenkrebs mittels pdgfra-, kit- oder kdg-gen als genmarker
GB0715087D0 (en) 2007-08-03 2007-09-12 Summit Corp Plc Drug combinations for the treatment of duchenne muscular dystrophy
CN101678107A (zh) 2007-08-03 2010-03-24 萨米特公开有限公司 用于治疗杜兴型肌营养不良的药物组合物
AU2008323770B2 (en) 2007-11-07 2014-08-07 Genentech, Inc. Compositions and methods for treatment of microbial disorders
EP2328908A4 (de) 2008-08-28 2012-11-28 Univ New York State Res Found Behandlung von amyloidosen anhand eines myelin-basischen proteins und fragmenten daraus
AU2009319772A1 (en) 2008-11-26 2010-06-03 Centocor Research & Development, Inc. Compositions and methods for regulating collagen and smooth muscle actin expression by SERPINE2
EP2213682A1 (de) 2009-01-30 2010-08-04 Institut Curie TSLP fördert Immunevasion und Persistenz von Viren
EP2266550A1 (de) 2009-06-15 2010-12-29 Institut Curie Antagonisten von ß-Catenin zur Prävention und/oder Behandlung neurodegenerativer Erkrankungen
ES2599076T3 (es) 2009-09-02 2017-01-31 Genentech, Inc. Smoothened mutante y métodos de utilización del mismo
JP6016636B2 (ja) 2009-10-15 2016-10-26 ジェネンテック， インコーポレイテッド 改変したレセプター特異性を持つキメラ線維芽細胞増殖因子
BR112012009409A2 (pt) 2009-10-22 2017-02-21 Genentech Inc método de identificação de uma substância inibidora, molécula antagonista, ácido nucleico isolado, vetor, célula hospedeira, método para fabricar a molécula, composição, artigo de fabricação, método de inibição de uma atividade biológica, método de tratamento de uma condição patológica, método para detectar msp em uma amostra e método para detectar hepsina em uma amostra
TWI507524B (zh) 2009-11-30 2015-11-11 Genentech Inc 診斷及治療腫瘤之組合物及方法
WO2011106297A2 (en) 2010-02-23 2011-09-01 Genentech, Inc. Compositions and methods for the diagnosis and treatment of tumor
JP6012591B2 (ja) 2010-04-12 2016-10-26 ソマロジック, インコーポレイテッドSomaLogic, Inc. β−ＮＧＦに対するアプタマー及びβ−ＮＧＦ介在疾患及び障害の治療におけるその使用
CN102958941A (zh) 2010-05-03 2013-03-06 霍夫曼-拉罗奇有限公司 用于肿瘤诊断和治疗的组合物和方法
ES2588981T3 (es) 2010-10-05 2016-11-08 Genentech, Inc. Smoothened mutante y métodos de uso de la misma
WO2014154898A1 (en) 2013-03-29 2014-10-02 Institut National De La Sante Et De La Recherche Medicale (Inserm) Prognosis and treatment of cancers
WO2015116902A1 (en) 2014-01-31 2015-08-06 Genentech, Inc. G-protein coupled receptors in hedgehog signaling
CA2937539A1 (en) 2014-02-04 2015-08-13 Genentech, Inc. Mutant smoothened and methods of using the same
JP2018512597A (ja) 2015-02-04 2018-05-17 ジェネンテック， インコーポレイテッド 突然変異体スムースンド及びその使用方法
CA3019952A1 (en) 2016-02-04 2017-08-10 Curis, Inc. Mutant smoothened and methods of using the same

Family Cites Families (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US4458066A (en) * 1980-02-29 1984-07-03 University Patents, Inc. Process for preparing polynucleotides
WO1989005853A1 (en) * 1987-12-15 1989-06-29 Synthetic Genetics Nucleic acid chelate conjugate as therapeutic and diagnostic agents

Also Published As

Publication number Publication date
CA2071483C (en) 2001-04-17
EP0498843A4 (en) 1992-11-04
WO1991006629A1 (en) 1991-05-16
EP0498843A1 (de) 1992-08-19
KR920702409A (ko) 1992-09-04
AU6724590A (en) 1991-05-31
DE69027443D1 (de) 1996-07-18
EP0498843B1 (de) 1996-06-12
DE69027443T2 (de) 1998-03-19
JPH05504553A (ja) 1993-07-15
AU653504B2 (en) 1994-10-06
CA2071483A1 (en) 1991-04-25

Similar Documents

Publication Publication Date Title
ATE139255T1 (de) Oligonukleotidanaloga mit neuartigen bindungen
EP0643720A4 (en) Binding competent oligomers containing 2', 5' linkages.
CA2266748A1 (en) Three component chimeric antisense oligonucleotides
EP1104303A4 (de) Kohlehydraten oder 2'-modifizierten oligonukleotiden mit alternierenden internukleoside-bindungen
ATE373671T1 (de) Aminooxy-modifizierte oligonukleotide
CA2006008A1 (en) Method for making synthetic oligonucleotides which bind specifically to target sites on duplex dna molecules, by forming a colinear triplex, the synthetic oligonucleotides and methods of use
EP1097162A4 (de) Oligonukleotide mit für bindungstaschen spezifischen chiralen phosphorothioat-internukleosidbindungen
DE69403642D1 (de) 7-deazapurin modifizierte oligonukleotide
BR9206049A (pt) Composto, processos para preparar o composto, para o reconhecimento específico por sequência de um polinucleotídio de filamento duplo, para modular a expressão de um gene em um organismo, para tratar as condições associadas com produção de proteínas indesejada em um organismo, para induzir a degradação de DNA ou RNA em células de um organismo e para exterminar células ou vírus e composição farmacêutica
ATE239090T1 (de) Methode zum generieren von einzelsträngigen dna molekülen
ATE216705T1 (de) Antisense-oligonukleotidmodulation der raf- genexpression
DK0549615T3 (da) Sukkermodificerede oligonukleotider der påviser og modulerer genekspression
FI925103A0 (fi) Antisense-inhibitorer av humant immunbristvirus
WO1999009154A3 (en) Novel hiv-specific synthetic oligonucleotides and methods of their use
CA2089666A1 (en) Oligonucleotides for modulating the effects of cytomegalovirus infections
ATE221127T1 (de) Über chirale phosphoratome gebundene oligonukleotide
BR8805646A (pt) Processo para amplificacao de genes estaveis em adn cromossomico de microorganismos procarioticos
NZ331358A (en) Methoxyethoxy oligonucleotides for modulation of protein kinase c expression
WO1995003406A3 (en) Enhancement of oligonucleotide inhibition of protein production, cell proliferation, and/or multiplication of infectious disease pathogens
WO2000008140A3 (en) Antisense oligonucleotides for the inhibition of vegf expression

Legal Events

Date Code Title Description
RER Ceased as to paragraph 5 lit. 3 law introducing patent treaties